This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

CTI Announces Data Presentations At The 18th Congress Of The European Hematology Association

SEATTLE, June 11, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentation of data highlighting PIXUVRI ® (pixantrone), the first approved treatment in the European Union for aggressive B-cell non-Hodgkin lymphoma (NHL) for adult patients who have failed 2 to 3 prior lines of therapy, and results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, a novel, oral JAK2/FLT3 inhibitor, at the 18 th Congress of the European Hematology Association (EHA) Annual Meeting, June 13-16, 2013 in Stockholm, Sweden.

"At EHA, we plan to present further analyses of the final safety and efficacy data from our EXTEND pivotal trial of PIXUVRI that we believe expand our understanding of the potential clinical benefit for patients with aggressive B-cell NHL who had received 2 to 3 prior regimens," said Jack Singer, M.D., Executive Vice President, Global Medical Affairs and Translational Medicine at CTI. "In addition, at EHA, results from a pooled integrated safety analysis from four Phase 1 and 2 clinical trials will be presented that quantify clinical toxicities of pacritinib, our novel, oral JAK2/FLT3 inhibitor currently being investigated in a Phase 3 clinical program."

Information regarding the EHA presentations is below. Full abstracts can be viewed at the EHA website.

Abstract Number: P310Poster Title: Pixantrone monotherapy in histologically confirmed, relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: Post-hoc analyses from a Phase 3 trialPresentation Date/Time/Location: Friday, June 14, 5:45 to 7:00 p.m. CEST, Poster HallFirst Author: Dr. Ruth Pettengell, St. George's Hospital, London, United Kingdom

Abstract Number: P278Poster Title: Safety overview of phase I-II studies of pacritinib, a non-myelosuppressive JAK2/FLT3 inhibitor, in patients with hematological malignanciesPresentation Date/Time/Location: Friday, June 14, 5:45 to 7:00 p.m. CEST, Poster Hall First Author: Dr. S. Verstovsek, MD Anderson Cancer Center, Houston, United States

Abstract Number: P983Poster Title: Characterization of the pharmacokinetic and pharmacodynamic properties of pacritinib, a novel oral JAK2/FLT3 inhibitor, in patients with myelofibrosis, AML and lymphoma Presentation Date/Time/Location: Poster session, Saturday, June 15, 5:45 to 7:00 p.m. CEST, Poster HallFirst Author: Dr. Suliman Al-Fayoumi, Cell Therapeutics, Seattle, United States

About PIXUVRI (pixantrone)

PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Unlike related compounds, PIXUVRI forms stable DNA adducts and in preclinical models has superior anti-lymphoma activity compared to related compounds. PIXUVRI was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite -- both of which are the putative mechanisms for anthracycline induced acute and chronic cardiotoxicity. These novel pharmacologic properties allow PIXUVRI to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs